Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (49)	4/17/1998 6:16:00 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 626

Sturza in his report issued today reiterates his strong buy on Titan with a target price of $15 in one year. He explains that the delay in the Phase III iloperidone trial was caused by the transfer of iloperidone manufacturing from the Hoechst Marion Roussel facility to their(Novartis) plant. This would avoid any problems with manufacturing later when they are ready to market the drug upon FDA approval. Also the start of the two Phase II trials of Pivanex and CeaVac are expected within the next three months. Pivanex for non-small cell lung cancer and CeaVac for colon cancer.